Evidence map›Paper›PMID 29920520›Full record

ArticlePloS one2018

Context-dependent expression of a conditionally-inducible form of active Akt.

Soyeon Park, Robert E Burke, Tatyana Kareva, Nikolai Kholodilov, Pascaline Aimé, Thomas F Franke, Oren Levy, Lloyd A Greene

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Soyeon ParkDepartment of Biological Sciences, Columbia University, New York, New York, United States of America.
Robert E BurkeDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.
Tatyana KarevaDepartment of Neurology, Columbia University Medical Center, New York, New York, United States of America.
Nikolai KholodilovDepartment of Neurology, Columbia University Medical Center, New York, New York, United States of America.
Pascaline AiméDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.
Thomas F FrankeDepartment of Neuroscience, Icahn School of Medicine at Mt Sinai, New York, New York, United States of America.
Oren LevyDepartment of Neurology, Columbia University Medical Center, New York, New York, United States of America.
Lloyd A GreeneDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.ORCID 0000-0002-3225-5521
Columbia University Irving Medical Center · USColumbia University · USIcahn School of Medicine at Mount Sinai · US

Funding

NEUROTROPHIC FACTOR DEPRIVATION AND NEURONAL CELL DEATHR01NS033689 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GREENE, LLOYD A · 1995 to 2017
$8.9M
Neuron death in Parkinson's disease: The role of Trib3R01NS072050 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GREENE, LLOYD A · 2012 to 2022
$3.7M
NINDS NIH HHS R01 NS033689NINDS NIH HHS R01 NS072050
6 · The paper itself

Abstract

Akt kinases are key signaling components in proliferation-competent and post-mitotic cells. Here, we sought to create a conditionally-inducible form of active Akt for both in vitro and in vivo applications. We fused a ligand-responsive Destabilizing Domain (DD) derived from E. coli dihydrofolate reductase to a constitutively active mutant form of Akt1, Akt(E40K). Prior work indicated that such fusion proteins may be stabilized and induced by a ligand, the antibiotic Trimethoprim (TMP). We observed dose-dependent, reversible induction of both total and phosphorylated/active DD-Akt(E40K) by TMP across several cellular backgrounds in culture, including neurons. Phosphorylation of FoxO4, an Akt substrate, was significantly elevated after DD-Akt(E40K) induction, indicating the induced protein was functionally active. The induced Akt(E40K) protected cells from apoptosis evoked by serum deprivation and was neuroprotective in two cellular models of Parkinson's disease (6-OHDA and MPP+ exposure). There was no significant protection without induction. We also evaluated Akt(E40K) induction by TMP in mouse substantia nigra and striatum after neuronal delivery via an AAV1 adeno-associated viral vector. While there was significant induction in striatum, there was no apparent induction in substantia nigra. To explore the possible basis for this difference, we examined DD-Akt(E40K) induction in cultured ventral midbrain neurons. Both dopaminergic and non-dopaminergic neurons in the cultures showed DD-Akt(E40K) induction after TMP treatment. However, basal DD-Akt(E40K) expression was 3-fold higher for dopaminergic neurons, resulting in a significantly lower induction by TMP in this population. Such findings suggest that dopaminergic neurons may be relatively inefficient in protein degradation, a property that could relate to their lack of apparent DD-Akt(E40K) induction in vivo and to their selective vulnerability in Parkinson's disease. In summary, we generated an inducible, biologically active form of Akt. The degree of inducibility appears to reflect cellular context that will inform the most appropriate applications for this and related reagents.

Indexed as

Protein EngineeringAnimalsBrainCell Cycle ProteinsCell DeathCell ProliferationEnzyme InductionForkhead Transcription FactorsGene ExpressionHEK293 CellsHumansMiceMutationNeuronsPhosphorylationProtein DomainsCell Cycle ProteinsForkhead Transcription FactorsFOXO4 protein, humanProto-Oncogene Proteins c-aktTranscription Factors

Identifiers

PMID29920520
PMCPMC6007834
OpenAlexW2809529464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.